Predict your next investment

Corporate Venture
boxercap.com

See what CB Insights has to offer

Investments

111

Portfolio Exits

40

About Boxer Capital

Boxer Capital is a vehicle for Tavistock Life Science's investment in a portfolio of public companies and private equity crossover opportunities. Boxer Capital leverages its internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for its investor the Tavistock Group. Boxer Capital has a focus on biotechnology drug development companies across multiple therapeutic indications.

Boxer Capital Headquarter Location

P.O. Box 9000

Windermere, Florida, 34786,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Boxer Capital News

Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology

Jan 19, 2022

Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75M Series A financing. The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors along with existing Seed investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. The post Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology appeared first on BioBuzz.

Boxer Capital Investments

111 Investments

Boxer Capital has made 111 investments. Their latest investment was in Ceptur Therapeutics as part of their Series A on January 1, 2022.

CBI Logo

Boxer Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/19/2022

Series A

Ceptur Therapeutics

$75M

Yes

3

1/14/2022

Series A

Alterome Therapeutics

$64M

Yes

Nextech Invest, OrbiMed Advisors, Undisclosed Investors, and Vida Ventures

4

11/3/2021

Series B

Shoreline Biosciences

$140M

No

2

9/1/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/1/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/19/2022

1/14/2022

11/3/2021

9/1/2021

6/1/2021

Round

Series A

Series A

Series B

Series B

Series B

Company

Ceptur Therapeutics

Alterome Therapeutics

Shoreline Biosciences

Subscribe to see more

Subscribe to see more

Amount

$75M

$64M

$140M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Nextech Invest, OrbiMed Advisors, Undisclosed Investors, and Vida Ventures

Sources

3

4

2

10

10

Boxer Capital Portfolio Exits

40 Portfolio Exits

Boxer Capital has 40 portfolio exits. Their latest portfolio exit was Tyra Biosciences on September 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2021

IPO

$99M

4

8/5/2021

Acquired

$99M

13

7/29/2021

IPO

$99M

2

6/25/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/25/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2021

8/5/2021

7/29/2021

6/25/2021

6/25/2021

Exit

IPO

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

13

2

10

10

Boxer Capital Team

5 Team Members

Boxer Capital has 5 team members, including current Senior Vice President, Dominik Naczynski.

Name

Work History

Title

Status

Dominik Naczynski

Senior Vice President

Current

Norman Zhou

Senior Vice President

Current

Mac Dabah

Managing Director

Current

Christopher Fugelsang

Managing Director

Current

Christopher Fuglesang

Tavistock Group, Perkins Coie, and Eidogen-Sertanty

Founder

Former

Name

Dominik Naczynski

Norman Zhou

Mac Dabah

Christopher Fugelsang

Christopher Fuglesang

Work History

Tavistock Group, Perkins Coie, and Eidogen-Sertanty

Title

Senior Vice President

Senior Vice President

Managing Director

Managing Director

Founder

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.